Clinical Trial

Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure

Study acronym: AGORAC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is that validation of the non-invasive biomarkers of the AGORA algorithm should make it possible to select patients with a very low immunological risk of graft failure to authorize safe minimization of their immunosuppression for adult patients at one-year post kidney transplantation. The main question of the AGORAC trial is to demonstrate the impact of TACROLIMUS minimization using AGORA algorithm compared to standard of care on the kidney function 18 months after the minimization period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-23; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2024-12-12
Trial Details
NCT Number NCT06235892
Lead Sponsor Nantes University Hospital
Conditions Organ Grafts
Enrollment 300 participants
Start Date 2024-12-10
Primary Completion 2028-06-10 (estimated)
Study Completion 2028-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-03